Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
Galimberti
Sara
S
Canestaro
Martina
M
Ciancia
Eugenio
E
Fazzi
Rita
R
Marasca
Roberto
R
Petrini
Mario
M
D001897:Boronic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D000069286:Bortezomib; D003114:Colony-Forming Units Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000503:physiopathology; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D046509:Tissue Culture Techniques
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib